Last 12 months
Inside the activity.
0 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 02, 2019 Filed Apr 3, 2019 23:03 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 6,135 | $5.28 | $32,392.80 |
DisclosureSEC source: 0001209191-19-023479 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 23:02 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 2,942 | $25.17 | $74,050.14 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,603,779 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.87 to $25.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 02, 2019 Filed Apr 3, 2019 23:02 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 3,200 | $24.52 | $78,464.00 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,606,721 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.87 to $24.86 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 02, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,242 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · derivative · entry 15 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,613 Underlying: Common Stock · 6,242 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 02, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 9,445 | $25.29 | $238,864.05 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 8 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 132,670 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.00 to $25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F9 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| April 02, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 3,442 | $25.15 | $86,566.30 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.82 to $25.65 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 2,800 | $24.51 | $68,628.00 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,442 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.81 to $24.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 02, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 6,242 | $5.28 | $32,957.76 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: This Form 4 amendment is being filed to correct an omission on the Form 4 filed on behalf of the Reporting Person on April 3, 2019. The original Form 4 filed did not reflect an additional 107 shares exercised from outstanding stock options and sold on April 2, 2019 pursuant to the Issuer's 10b5-1 plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:03 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,775 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-023479 · doc4.xml · derivative · entry 14 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,855 Underlying: Common Stock · 5,775 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:03 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 5,775 | $23.91 | $138,080.25 |
DisclosureSEC source: 0001209191-19-023479 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.35 to $24.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:03 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-19-023479 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:02 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 6,050 | $23.91 | $144,655.50 |
DisclosureSEC source: 0001209191-19-023478 · doc4.xml · nonDerivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,609,921 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.35 to $24.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| April 01, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,775 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · derivative · entry 14 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,855 Underlying: Common Stock · 5,775 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| April 01, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 5,775 | $23.91 | $138,080.25 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.35 to $24.18 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 01, 2019 Filed May 10, 2019 21:34 UTC Amendment |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-19-029049 · doc4a.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2019 Filed Apr 10, 2019 01:27 UTC |
BRATTON DOUGLAS K10% owner
Neuro Line Partners LP10% owner
Bratton Capital Management, L.P.10% owner
Bratton Capital Inc.10% owner
|
OtherCommon Stock | 158,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010426 · doc4.xml · nonDerivative · entry 1 BRATTON DOUGLAS K · CIK 0001281933 · 10% owner Neuro Line Partners LP · CIK 0001723842 · 10% owner Bratton Capital Management, L.P. · CIK 0001723787 · 10% owner Bratton Capital Inc. · CIK 0001723783 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Neuro Line Partners, L.P. Disclosed balance after: 953,035 F1 · price: Pro rata in-kind distribution of shares of common stock, par value $0.01 per share, (the "Common Stock") of Denali Therapeutics Inc. from Neuro Line Partners, L.P. ("Neuro Line") to limited partners of Neuro Line without consideration. F2 · ownership.nature: The shares of Common Stock reported in Column 5 are held directly by Neuro Line. The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. F3 · ownership.nature: (Continued from Footnote 2) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 21:49 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-020068 · doc4.xml · derivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,630 Underlying: Common Stock · 500 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 21:49 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 500 | $25.01 | $12,505.00 |
DisclosureSEC source: 0001209191-19-020068 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.00 to $25.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 21:49 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 500 | $5.28 | $2,640.00 |
DisclosureSEC source: 0001209191-19-020068 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 21:49 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 500 | $25.01 | $12,505.00 |
DisclosureSEC source: 0001209191-19-020068 · doc4.xml · nonDerivative · entry 3 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 142,115 F3 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $25.00 to $25.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F5 · ownership.nature: The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 22:02 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 1,512 | $24.33 | $36,786.96 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 655,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $24.09 to $24.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 13, 2019 Filed Mar 13, 2019 22:02 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 1,000 | $23.60 | $23,600.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 656,601 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $23.04 to $24.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 12, 2019 Filed Mar 13, 2019 22:02 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 2,513 | $22.40 | $56,291.20 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 657,601 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.01 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:02 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 275 | $21.80 | $5,995.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,114 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.79 to $21.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:02 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 2,200 | $21.20 | $46,640.00 |
DisclosureSEC source: 0001209191-19-019213 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 660,389 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.73 to $21.70 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 23:18 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 6,141 | $21.97 | $134,917.77 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 6 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,615,971 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.42 to $22.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,862 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · derivative · entry 14 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,130 Underlying: Common Stock · 5,862 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 5,862 | $21.96 | $128,729.52 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 11 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.51 to $22.32 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 05, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,862 | $5.28 | $30,951.36 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 10 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:18 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 1,700 | $22.83 | $38,811.00 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 5 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,622,112 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.61 to $23.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:18 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 4,442 | $21.87 | $97,146.54 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 4 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,623,812 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.54 to $22.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,863 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · derivative · entry 13 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,992 Underlying: Common Stock · 5,863 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 1,600 | $22.84 | $36,544.00 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 9 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.61 to $23.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 4,263 | $21.87 | $93,231.81 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 8 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.54 to $22.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 04, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,863 | $5.28 | $30,956.64 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 7 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:18 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 2,050 | $22.91 | $46,965.50 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,628,254 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.82 to $23.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:18 UTC |
Watts Ryan J.Director · President and CEO
|
SaleCommon Stock | 4,000 | $22.19 | $88,760.00 |
DisclosureSEC source: 0001209191-19-016931 · doc4.xml · nonDerivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,630,304 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.76 to $22.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,775 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · derivative · entry 12 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,855 Underlying: Common Stock · 5,775 shares Expires 2027-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Of the total 187,500 shares granted, 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 1,951 | $22.92 | $44,716.92 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 6 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $22.82 to $23.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
SaleCommon Stock | 3,824 | $22.17 | $84,778.08 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 5 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,951 F4 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $21.78 to $22.72 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:21 UTC |
Ho CaroleChief Medical Officer
|
Exercise / conversionCommon Stock | 5,775 | $5.28 | $30,492.00 |
DisclosureSEC source: 0001209191-19-016941 · doc4.xml · nonDerivative · entry 4 Ho Carole · CIK 0001724605 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 23:30 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 1,700 | $20.24 | $34,408.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 6 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 662,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $20.11 to $20.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 12, 2019 Filed Feb 12, 2019 23:30 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 800 | $19.73 | $15,784.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 5 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 664,289 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.05 to $19.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 23:30 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 1,266 | $19.35 | $24,497.10 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 4 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 665,089 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.18 to $19.46 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 23:30 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 1,234 | $18.74 | $23,125.16 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 3 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 666,355 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.18 to $19.16 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC |
Watts Ryan J.Director · President and CEO
|
GrantStock Option (right to buy) · Derivative | 281,600 | $0.00 Strike: $18.13 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 3 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,600 Underlying: Common Stock · 281,600 shares Expires 2029-02-07 F4 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 8, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC |
Watts Ryan J.Director · President and CEO
|
GrantRestricted Stock Units · Derivative | 35,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 2 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,200 Underlying: Common Stock · 35,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 25% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F3 · derivative.expiration_date: 25% of the restricted stock units shall vest on February 8, 2020 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:54 UTC |
Watts Ryan J.Director · President and CEO
|
GrantRestricted Stock Units · Derivative | 11,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-009061 · doc4.xml · derivative · entry 1 Watts Ryan J. · CIK 0001724310 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,031 Underlying: Common Stock · 11,031 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: 50% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. F2 · derivative.expiration_date: 50% of the restricted stock units shall vest on February 8, 2020 and the remaining 50% of the restricted stock units shall vest on February 8, 2021, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 23:30 UTC |
Schuth Alexander O.COO and Secretary
|
SaleCommon Stock | 2,500 | $18.11 | $45,275.00 |
DisclosureSEC source: 0001209191-19-009482 · doc4.xml · nonDerivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 667,589 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.26 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 22:59 UTC |
Schuth Alexander O.COO and Secretary
|
GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $17.99 | $0.00 |
DisclosureSEC source: 0001209191-19-009077 · doc4.xml · derivative · entry 2 Schuth Alexander O. · CIK 0001724311 · COO and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Common Stock · 136,000 shares Expires 2029-02-06 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 7, 2020, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.